CANARY BIOTECH & HEALTHCARE INVESTOR ROADSHOW

Size: px
Start display at page:

Download "CANARY BIOTECH & HEALTHCARE INVESTOR ROADSHOW"

Transcription

1 CANARY BIOTECH & HEALTHCARE INVESTOR ROADSHOW Wednesday 8 July 2015: isonea will be presenting at the Canary Biotech & Healthcare Investor Roadshow to be held on Wednesday 8 th July in Melbourne and Thursday 9 th July in Sydney. The investor presentation is attached and the key messages for new investors are outlined below: Unique first mover advantage with its proprietary ARM technology to detect and measure wheeze A multi-product portfolio in respiratory health not based on one product and thus lower risk for investors. Core technology that has been used by world leading respiratory physicians and scientists. Forefront of digital/mobile health platforms that will change asthma care Huge global market with over 300 million people with asthma Asthma is a global burden for health systems Business turnaround by new Board and Management team Clear pathway forward to monetise the business Valuation potential Substantial transactions starting to occur in digital health Leon L Huillier Chairman +61 (0)

2 World s First Digital Wheeze Detection Technology for the Management of Asthma An Australian owned company with Israeli & Australian technology 1

3 Changing Asthma Care About isonea World s First Digital Wheeze Detection Technology for the Management of Asthma isonea is a medical device company with an innovative portfolio of wheeze detection & measurement products that help patients & physicians improve asthma management and reduce preventable emergency room visits, hospitalisation & unnecessary worry & suffering. isonea has unique leading edge acoustic sensors, proprietary algorithms and software platforms to objectively detect and measure wheeze, an important symptom of asthma. Its latest product, AirSonea, is a remote patient monitoring device and app. 2

4 Why investnow? now? Why The company is now well positioned to create shareholder value and has substantial value creation potential: Unique first mover advantage with its proprietary ARM technology to detect and measure wheeze A multi product portfolio in respiratory health not based on one product and thus lower risk for investors. Core technology that has been used by world leading respiratory physicians and scientists. Forefront of digital/mobile health platforms that will change asthma care Huge global market with over 300 million people with asthma Asthma is a global burden for health systems Business turnaround by new Board and Management team Clear pathway forward to monetise the business Valuation potential: Substantial transactions starting to occur in digital health 3

5 Have you noticed you ve been wheezy, breathless or coughing lately? Are you using your medication more? Is your asthma interfering with you usual activities? Asthma Australia Spring 2014 Update 4

6 Changing Asthma Care Asthma Symptoms The main symptoms of asthma: Wheezing Shortness of breath A tight chest Coughing Airflow Limitation When airways become inflamed, flow pressure changes during respiration causing the airway wall to flutter. This flutter results in acoustic energy, or wheeze. The flutter or wheeze is a manifestation of airway flow limitation. If an infant presents with frequent and/or severe episodes of recurrent wheezing they should be diagnosed and managed as asthma, unless there is evidence to the contrary. Global Asthma Report

7 First Mover Advantage/Computerised Wheeze Detection isonea continues to have a first mover advantage with its unique proprietary Acoustic Respiratory Monitoring(ARM ) algorithm technology. Our ARM technology records airway sounds to detect continuous adventitious breath sounds and measure the extent of wheezing caused by airway obstruction. The measurement is presented as WheezeRATE. isonea devices work like a stethoscope utilising special contact microphones, or acoustic sensors, to pick up breath sounds from the lungs at the windpipe(trachea), and in the clinical devices, the chest. Actual wheezing event from an asthma patient, recorded with isonea s ARM technology. 6

8 A Multi-Product Portfolio to Lower Risk for Investors The company s portfolio of computerised wheeze detection products and apps AirSonea, WHolter, SonoSentry, WheezoMeter, PulmoTrack and the AsthmaSense App Have been approved by the Australian TGA and carry the European Union s CE mark. All except AirSonea have US FDA clearance 7

9 Remote (Home) Monitoring Products Health authorities universally agree effective tools to improve patient self-management of asthma are critical. AirSonea Asthma Wheeze Monitor Device& App The convenient and easy-to-use AirSonea device connects via Bluetooth with the asthma management smartphone app to detect and measure wheeze. The 30 second recording and WheezeRATE algorithm analysis takes place within the app with measurements results displayed on the smartphone screen. The results and actual sound files are automatically uploaded to the cloud servers so the entire history can be reviewed and shared with doctors and other healthcare providers via secure . The app features asthma management diary features; medication usage and reminders, and symptoms and triggers to help asthma sufferers gain a better understanding of how their condition affects them and importantly, help them better adhere to their treatment plans. Further features including weather conditions and pollen count are planned. The development of robust acoustic devices for use at the bedside as exemplified by electronic stethoscopes paired with small convenient recorders and perhaps in the form of a smartphone with an app - may provide the long-awaited portable objective means to record, analyse, and store lung sounds just as any other clinical information is measured and stored. This development will make sound tracking possible, further enhancing the usefulness of auscultation. Fundamentals of Lung Auscultation by Abraham Bohadana, M.D.Gabriel Izbicki, M.D. &SteveSKramanM.D.New England Journal of Medicine 370;9 NEJM:ORG FEBRUARY 20,

10 Remote (Home) Monitoring Products SonoSentry 1 (WheezoMeter ) and New SonoSentry 2 Prototype. Standalone device with inbuilt LCD screen. isonea has achieved the first clearance of an Overthe-Counter (OTC) wheeze detection device in the United States. With FDA clearance, the company can market the device in the USA as an OTC product without the need for the purchaser to obtain a prescription from a medical practitioner. Computation is performed on the device and a phone, phone service or a server is not required (however, there is additional value in being able to extract information from the device to be placed onaserver). isonea is actively investigating the potential to substantially lower the costs of production of SonoSentry 2 to evaluate a commercial launch of this product in China and developing countries. 9

11 Home Monitoring: Nocturnal WHolter Symptoms of asthma, including wheeze, are generally worse at night and early morning. TheWHolterisdesignedfor8-24hourhomeambulatory recording (nocturnal, wheeze, cough). This option of monitoring Asthma patients and collecting data for a period of time in their own home is important and has excellent potential to develop service and consumables revenues around it. WHolter uses PulmoTrack software andcurrentlyconnectstoapcviausb. Next Step: upgrade to wireless capability and app function 10

12 Clinical/Hospital Monitoring PulmoTrack Wheeze Detection Computerised PulmoTrack is isonea s foundation product, designed for hospital/clinic-based real-time monitoring of wheeze and cough in the management of acute, severe asthma in the ER and IC, and for Pediatric Pulmonary Function Testing and Sleep Labs. The PulmoTrack module has a wireless connection toapc. In a recent study conducted at the Department of Neonatology, Charité University Medical Centre, Berlin, Germany, wheezes were detected using the PulmoTrack Model an instrument developed for continuous tracking and recording of breathing sounds and the detection of wheezing. Computerised wheeze detection is feasible during the first year of life. This method is more objective and can be more readily standardised than subjective auscultation, providing quantitative and noninvasive information about the extent of wheezing. Puder et al BMC Paediatrics

13 Core ARM Technology Research Published by World leading Physicians History of 14 clinical publications, using isonea s proprietary Acoustic Respiratory Monitoring(ARM ) technology. ORIGINAL ARTICLE JOURNAL OF ASTHMA Vol. 41, No. 8, pp , 2004 Wheeze Detection: Recordings vs. Assessment of Physician and Parent M. L. Levy, 1,4,* S. Godfrey, 2,# A. Sheikh, 4 W. Hanekom, 5 Ambulatory Care Nurses, 5 A. Bush, 6 and P. Lachman 1. Kenton Bridge Medical Centre, London, UK 2. Hadassah University Hospital, Jerusalem, Israel 3. Karmel Medical Acoustic Technologies Ltd., Yokneam Ilit, Israel 4. Division of Community Health Sciences, GP Section, University of Edinburgh, Edinburgh, Scotland 5. Northwick Park Hospital, London, UK 6. Royal Brompton Hospital, London, UK 12

14 Globally Renowned Physicians Speak at Asthma Conferences Two of the globally renowned physicians who have published on wheeze detection were keynote speakers at recent major asthma conferences held in Australia during 2015 Professor Andrew Bush Dr Mark Levy Professor Andrew Bush Professor of Paediatric Respirology, Royal Brompton Hospital, NHS Foundation Trust. Faculty of Medicine, National Heart and Lung Institute. DrMarkLevy Respiratory lead for the Harrow Clinical Commissioning Group in Harrow, London. Senior Clinical Research Fellow, University of Edinburgh( ). 13

15 isonea s Medical & Scientific Advisors are Internationally Respected Professor Noam Gavriely, MD, D.Sc He has been conducting basic and applied research on pulmonary acoustics for over 25 years and is an international authority in this field. He is extensively published in various aspects of breath sounds, including the 1995 CRC press book on "Breath Sounds Methodology", and holds multiple US and international patents on phonopneumography and other aspects of breath sounds monitoring. Dr. Gavriely received his M.D. and D.Sc. from the Technion-Israel Institute of Technology and did his postdoctoral fellowship at the Harvard School of Public Health and the Brigham and Women s Hospital. Prof. Simon Godfrey, MD, PhD, FRCP, FRCPCH is Emeritus Professor of Pediatrics at the Hadassah-Hebrew University, Jerusalem. His major clinical interests are in pediatric pulmonology and asthma. His main research interests are in pediatric pulmonary physiology, infant lung function, asthma, bronchial provocation and the application of novel investigative techniques for the diagnosis and management of pediatric pulmonary diseases. Prof. Godfrey has published over 190 original papers, 16 books and contributed numerous chapters to other books, in addition to written editorials on pediatric pulmonary topics. 14

16 isonea at Forefront of Explosive Field of Digital Health First wave: Fitness and wellness devices The first wave of this trend is already evident in the rapid consumer adoption of wearable sensors and smart watches which produce data related to physical activity, although of limited or little clinical value. Second wave: Digital health platforms for complex diseases The second wave includes the monitoring of symptoms and behaviour in chronic disease management, such as wheeze detection and measurement in asthma, glucose monitoring for diabetics. Thirdwave:Bigdata The third wave will come with algorithms and software that can sense and interpret multiple factors and conditions that could impact symptoms, in order to identify risks and issues alerts for avoidance. This aspect involves the collection and analysis of Big Data from multiple sources, including the networks of device users. 15

17 Remote Patient Monitoring: Key Driver of Growth Smartphones provide an engine for this change: It is estimated that there will be 10 billion mobile devices in use worldwide by We're all essentially surgically connected to our smartphones, and we're still in the early stages of realising their medical potential. Dr. Eric Topol, Director, Scripps Translational Science Institute #1 Most Influential Physician Executive in the USA, Modern Healthcare National Poll Health conscious consumers are already embracing self-management and this is evident in the growth of wearable fitness sensors such as Fitbit. The continued shift toward accountable care will encourage the adoption of remote patient monitors for chronic diseases like asthma, diabetes and cardiovascular illness, with the goal of keeping patients out of the hospital, lowering costs and improving care. 16

18 Digital Health Platforms Replace Outdated Technology Respiratory Digital Health: Asthma & COPD Sensors, apps, text and analytics to monitor and control symptoms. Convenient, effortless, objective symptom measurement - isonea Traditional Monitoring Peak Flow Meters Outdated technology, not suitable for children, patient compliance poor and considerable patient effort. isonea has broad patents that could provide barriers to entry 17

19 Huge Global Asthma Market 334 million people have asthma 14% of the world s children experience asthma symptoms 8.6% of young adults (aged 18-45) experience asthma symptoms Approximately 250,000 people die prematurely each year from asthma. Almost all these deaths are avoidable (WHO 2007) China: Over 30 million but probably closer to 100 million USA: 25 million, 10% of children Europe: 30 million UK: 5 million Australia: 2 million 18

20 Asthma is a Major Health Burden Theasthmaburdentosocietyismassiveintermsofasthma deaths, hospitalisation, emergency visits, missed days of schooling and work. IntheUSA,forexample: 5,000 deaths per annum 2 million emergency department visits 500,000 hospitalisations 27millionmisseddaysofschoolandwork Createsaburdencostofover$56billionannuallyor$2,200 per person including both the direct and indirect medical expenses associated with asthma, it is estimated that the total cost is closer to $82.5billion annually, or $3,300 per person. Source: US department of Health and Human Services CDC

21 Asthma is Poorly Controlled and New Tools are Essential Asthma is poorly controlled and new tools are needed to help patients. Nearly half of adults with asthma in Australia had poor asthma control and 29% needed urgent health care for asthmainthepreviousyearaccordingtoarecentstudypublishedinmedicaljournalofaustralia. 3 49%ofthepeoplewhohaddiedintheUKfromasthmain2012werebeingtreatedformildormoderateasthma whenitislikelythatmanyofthesepatientshadpoorlycontrolled,undertreatedasthma. 4 48%ofadultsdiagnosedwithasthmawhoweretaughthowtoavoidtriggersdidnotfollowmostofthisadvice 5 Medication adherence is poor. Data suggests approximately 30% of patients do not take their medications as prescribed. Although written asthma action plans have been recommended in national guidelines for the management of asthma for over 20 years,themajorityofpeoplewithasthmadonothaveone. Asthma in Australia 2011 The Australian Centre for Asthma Monitoring, Woodcock Institute of Medical Research 1. Centers for Disease Control and Prevention (CDC) : Asthma Statistics/Asthma Society of Canada, 2. Global Asthma Network: Global Asthma Report Medical Journal of Australia 202 (9) 18 May 2015: Asthma control in Australia: a cross-sectional web-based survey in a nationally representative population 4. Why Asthma Still Kills, The National Review of Asthma Deaths (NRAD) May Centers for Disease Control and Prevention, Vital Signs, May

22 Market Research: AirSonea an Important Management Tool isonea has conducted extensive market research in the US and Australia that shows our functional, user friendly product line will meet the expectations of our customer base that includes parents and patients, the medical profession, insurers, pharmacies and retailers. Key Findings: Parents Parents of children with asthma are constantly worrying about their child s health and wondering when the next attack will occur and what will trigger it. Theyadmittheycouldbemorediligentandnonefeelliketheyareincompletecontrol. They also find it difficult to articulate the severity of symptoms. Asthma Guilt is pervasive. It s a function of the pressure of day-to-day life overwhelming the best of intentions; coupled with the more reactive approach to an asthma attack rather than proactive management. They also find it difficult to articulate the severity of symptoms to doctors, a source of some frustration. Adults Adults with Asthma (secondary market) have more established knowledge of their asthma and know if I m wheezing or not. Certainly interested but not to the same degree as parents. 21

23 Key Findings: Medical Professionals Medical Professionals Interest in device: Intent to purchase the AirSonea wheeze monitoring device ranged from 60%to95%inthevariousstudies. isonea also conducted qualitative in-depth interviews with key asthma experts and a quantitative study with a total of 100 Australian GPs including 50 Paediatricians who routinely treat asthma. Results found that 80% of GPs and 62% of Paediatricians in the study would recommend isonea s new mobile wheeze monitoring system to their asthma patients. Providing additional scientific data on the technology would increase the percentage of these recommendations. In general, the product was perceived as an important management tool for patients who would benefit form more frequent home monitoring of asthma symptoms, which were characterised as 75% of patients with unstable asthma and approximately half of all patients with stable asthma. Physicians considered home monitoring of asthma very important, chiefly to assist in the management of asthma treatment plans and ensuring medication adherence. They noted that historically, the use of peak flow meters and diaries has been met with poor compliance and reliability. *The Independent consumer research studies were conducted by Dectiva LLC, Procter & Gamble Tremor, Galaxy Research, Consilium and Sweeney EY Research 22

24 Business Turnaround by New Board & Management Team The new Board appointed in February 2014 has delivered major changes to turnaround the business 1. The business structure has been dramatically simplified, costs reduced and streamlined for clearer focus 2. A totally new software IT infrastructure has been developed to support the AirSonea device and app. 3. Cashburnreducedfromnear$900,000pmtoaforecastcoreunderlyingcashburnofaround$240,000pm. 4. Intellectual Property Portfolio consolidated 5. Leading globally respected scientific advisors appointed 6. Improved relationships with leading clinicians, healthcare professionals and peak Asthma bodies established 7. Broader focus on the whole portfolio of products to open up substantially more commercial opportunities 23

25 Business Turnaround by New Board & Management Team The new Board appointed in February 2014 has delivered major changes to turnaround the business 1. Overall, the business structure has been dramatically simplified, costs reduced and streamlined for clearer focus and accountability and more robust financial controls Management are now based in Melbourne, Australia and Haifa, Israel. Senior Management previously resided in multiple locations including Maryland, Boston, San Diego and New York $2.5 million pa taken out of management and staff costs 2. A totally new software IT infrastructure has been developed to support the AirSonea device and app. Our new software is more robust, scalable and secure. Micro-processing upgrades have addressed firmware bugs. Further, it provides substantially faster analysis of breath recordings and an app with a more engaging user interface. The failed launch in Australia indicated web and app problems and the engagement of multiple service providers situated on four continents resulted in a high cost, over-engineered and incomplete IT infrastructure. 24

26 Business Turnaround by New Board & Management Team 3. Cash burn reduced from near $900,000 per month to a forecast underlying burn of around $240,000 per month. Estimated cash balance of $2.9 million as at June 30*. Net average monthly outgoing cash flows ($000) 881 High R & D spend * Prior to finalisation of Quarterly 4C statement. Forecast underlying cash burn 25

27 Business Turnaround by New Board & Management Team 4. Consolidated Intellectual Property Portfolio: One service provider to ensure our patent strategy is implemented and that our IP is secured in relevant jurisdictions. 5. Appointed leading globally respected scientific advisors: Prof Noam Gavriely& Prof Simon Godfrey 6. Established improved relationships with leading clinicians, healthcare professionals and peak Asthma bodies in Australia and overseas. 7. Broader focus on the whole portfolio of products to open up substantially more commercial opportunities in both the home/ambulatory market and in hospital and clinical settings. 26

28 isonea Current Partnerships Shartsis Friese LLP, USA Patents FAL Lawyers Australia EY Sweeney Market Research DKC Consultants Finance & Accounts Sterling Medical QA USA isonea Board Executive Chair isonea Israel R&D, Medical & Scientific Advisory The Wall Partnership User Interface R&D Marketing Refined Manufacturing China Two Bulls App Development Life is Digital Web/ hosting Grey Innovation Product Development 27

29 Clear Pathway Forward Building shareholder value through global and country partnerships either as joint ventures or sales and distribution agreements remains our core objective. Our pathway forward is two-fold and these steps are being managed in parallel 1. Commence commercial discussions with potential partners that include the worlds largest healthcare companies 2. Complete clinical trials on AirSonea overseas, especially in the important North American market 28

30 isonea brings Digital Health Capabilities to Worlds Largest Healthcare Companies Fitness & Wellness Devices Thermometer Weight Scale Step Counter Pulse Oximeter Heart Rate Monitor Blood Pressure Monitor Baby Monitor Chronic Disease Devices AirSonea Wheeze Monitor Smart Inhalers Blood Glucose Monitors Cardiology Patient Self- Management Smartphone Personal Computer Personal Health Diary Internet Healthcare System Family Carers Disease Management Hospitals & Healthcare Providers Insurance Companies isonea Potential Partnerships Medical Devices & Disease Management Philips, Omron, ResMed, GE Healthcare, CareFusion, Vectura, Propeller Health, Alere, Care Innovations, Dexcom, Withings Big Pharma GlaxoSmithKline, AstraZeneca, Schering-Plough, Boehringer Ingelheim, Novartis, Teva, Smartphone/Portable Health Devices Apple, Samsung, Xiaomi, Sony, Fitbit, Jawbone, ihealth Labs TeleHealth AT&T, Verizon, Telstra, Optus Digital Platforms Microsoft HealthVault, Qualcomm, Neusoft, Google, Yahoo 29

31 Complete Two AirSonea Clinical Trials Trial 1: The objective is to show AirSonea is at least as accurate as a consensus of a panel of physicians and trained experts in detecting and quantifying wheeze. In the last few years, 14 successful clinical studies have been conducted using isonea's proprietary ARM technology on patients with obstructive airway disease. Trial 2: Theobjectiveistostudytheefficacyofmanagingasthmainchildrenduringandafteranacuteattackusingthe AirSonea device to measure wheeze rate in an Urgent Care/Emergency Department setting. The company expects Trial 1 to be completed by the end of October and Trial 2 by year end. However, the number of variables in clinical trials make it difficult to accurately predict completion dates. 30

32 Valuation Upside: Transactions Now Occurring Wellness Devices Fitbit: IPO: $8 Billion Valuation. New fitness & wellness product Fitbit Surge tracks GPS, continuous heart rate, all-day activity stats and sleep, September Xiaomi: ihealth s small wellness business valued at over $125million. Asian smartphone giant, Xiaomi buys 20% stake in Andon s ihealth business for $25 million 31

33 Dexcom Complex Disease Device Dexcom market cap now $5.6 billion Dexcom Introduces Apps That Enable the First Ever Continuous Glucose Monitoring (CGM) on the Apple Watch Now People With Diabetes and Caregivers Have Access to Life-Saving Glucose Data in a Convenient and Discreet Manner Right from their Wrist Dexcom continuous glucose monitor (CGM) provides patients the opportunity to track their glucose levels and trends right on their wrist with the Apple Watch. Additionally, patients or "Sharers" can invite up to five people to view their glucose information and send an alert when the sharer's glucose levels are outside the norm. Continuous glucose monitoring is considered the most significant breakthrough in diabetes management in the past 40 years. Dexcom Stock Check 32

34 ResMed Complex Disease Device ResMed buys Irish Company, S+ in 2011 and launches consumer product in America in Peter Farrell: We have a consumer app and device called S+. It tracks every breath, gives you your sleep history. This is a consumer product. It was written up in The Wall Street Journal as the best. We ve sold thousands. Itwillbeherein2015. The S+ monitors breathing patterns and body movements without requiring uncomfortable wristbands, mattress strips or electrodes. The system allows consumers to log factors such as caffeine and alcohol intake, as well as exercise, to analyze patterns over time and deliver personalized sleep strategies. The capabilities of the S+ go beyond those of fitness devices available on the market because the S+ algorithm provides personalized suggestions informed by more than two million nights of proprietary sleep data. 33

35 Forward Looking Statements & Medical Device Risks Forward Looking Statements Certain statements made in this presentation are forward-looking statements. These forward looking statements are not historical facts but rather are based on isonea s current expectations, estimates and projections about the industry in which isonea operates, and its beliefs and assumptions. Words such as "anticipates," "expects," "intends,""plans,""believes,""seeks, "estimates, guidance and similar expressions are intended to identify forward looking statements and should be considered an at-risk statement. Such statements are subject to certain risks and uncertainties, particularly those risks or uncertainties inherent in the process of developing technology and in the endeavour of building a business around such products and services. These statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and other factors, some of which are beyond the control of isonea, are difficult to predict and could cause actual results to differ materially from those expressed or forecasted in the forward looking statements. isonea cautions shareholders and prospective shareholders not to place undue reliance on these forward-looking statements, which reflect the view of isonea only as of the date of this presentation. The forward looking statements made in this presentation relate only to events as of the date on which the statements are made. isonea will not undertake any obligation to release publicly any revisions or updates to these forward-looking statements to reflect events, circumstances or unanticipated events occurring after the date of this presentation except as required by law or by any appropriate regulatory authority. General Medical Device Risks Medical device R&D involves medical and scientific uncertainty and long lead times and there is no certainty that any particular event will occur within a certain time period. Technology changes in the medical device and digital health industry are accelerating and new technologies emerge. Market acceptance of medical devices is uncertain and can be impacted by difficulties in marketing, acceptance by patients and clinicians, delays in marketing and the advancement of new competitive products. Medical device R&D and manufacturing activities require funding over a long period of time and more working capital is often required to complete development and commercialisation of certain products. Government health regulations, which are subject to change, add uncertainty to obtaining approval to market medical devices. Obtaining, securing and maintaining rights to technology and patents are an integral part of securing potential product value and can lead to patent disputes. Thelossofkeypersonnelcanhaveanadverseimpact. Potential product liability risks and warranty claims are inherent in the manufacturing, marketing and use of human medical devices. 34

36 APPENDIX 35

37 Brief Company History Appendix APPENDIX isonea Limited (ISN) is an Australian owned, public company listed on the ASX. It is a developer, manufacturer and marketer of medical devices for the diagnosis and management of asthma and related chronic respiratory diseases. Brief History : Company Beginnings In 1996 Prof Noam Gavriely M.D. D.Sc. founded company Karmel Medical Acoustic Technologies (KMAT) in Haifa, Israel. The company s technology was based on innovations in the field of pulmonary acoustics developed by Prof Gavriely. His translation research applied the basic physics of sound into medical and nursing practice to enhance health outcomes and patient wellbeing. In 2006, KMAT (Israel) and Pulmosonix (Australia) were purchased by Salus Technologies, a listed Australian company. The group was renamed KarmelSonix Ltd. In 2011, the company name was changed to isonea Limited and a new Board of Directors and an American management team were appointed :AmajorstrategicerrorinSeptember2013 A major strategic error was made in 2011 with the decision to rush the design, development, manufacture and launch in Australia of a portable monitoring device, the AirSonea Asthma Wheeze Monitor and App. Successful FDA cleared clinical products were discontinued and the relationship with the foundation professors in Israel terminated. The September 2013 online launch failed. The hype around smartphones and mobile health applications gave investors unrealistic expectations of early success. The product had poor user experience and functionality, no brand recognition nor support from the medical profession and the broader asthma community. This expensive and ill-conceived online launch in September 2013 had a serious impact on the company s financial and cash position as sales revenue of only $19k resulted. 2014: Company Turnaround The company s financial position was deteriorating rapidly and a new commercially experienced Board was appointed. The Board now comprises of : Mr. Leon L Huillier(Executive Chairman), Mr. David Ashmore, Mr. Ross Blair-Holt, Dr. Timothy Oldham and Mr. John Ribot-de-Bresac. 2015: Appointed the company s original medical and scientific leaders, Prof Noam Gavriely as consultant and Emeritus Prof Simon Godfrey as Senior Scientific Advisor. 36

Health Care 2.0: How Technology is Transforming Health Care

Health Care 2.0: How Technology is Transforming Health Care Health Care 2.0: How Technology is Transforming Health Care Matthew Kaiser, CEBS, SPHR Director, HR Technology and Outsourcing Lockton Kansas City, Missouri The opinions expressed in this presentation

More information

Cellular Wireless technology: Creating a link between people and the healthcare community

Cellular Wireless technology: Creating a link between people and the healthcare community Cellular Wireless technology: Creating a link between people and the healthcare community Introduction Demands on health-care systems worldwide have increased to the point where the delivery and cost of

More information

Big Data Analytics Driving Healthcare Transformation

Big Data Analytics Driving Healthcare Transformation Big Data Analytics Driving Healthcare Transformation Greg Caressi SVP Healthcare & Life Sciences November, 2014 Six Big Themes for the New Healthcare Economy Themes Modernizing Care Delivery Clinical practice

More information

Simavita Australian investor briefing presentation

Simavita Australian investor briefing presentation Simavita Australian investor briefing presentation For Immediate Release: June 24, 2015 Sydney, Australia Simavita Limited ( Simavita or the Company ) (TSX-V: SV; ASX: SVA), a global leader in the digital

More information

For personal use only

For personal use only ACRUX (ACR) - ASX ANNOUNCEMENT 20 FEBRUARY 2014 ACRUX PROVIDES HALF YEAR UPDATE 2013 Highlights: Axiron sales milestone achieved US$25 million receivable early March 2014 Half-year financials: o Revenue

More information

Extending To Rural And Remote Australia A Multidisciplinary Continuing Professional Education Program On Child And Adolescent Health

Extending To Rural And Remote Australia A Multidisciplinary Continuing Professional Education Program On Child And Adolescent Health Extending To Rural And Remote Australia A Multidisciplinary Continuing Professional Education Program On Child And Adolescent Health Hilary Russell Director, Education and Quality Assurance Centre for

More information

OPKO Health to Acquire Bio-Reference Laboratories

OPKO Health to Acquire Bio-Reference Laboratories OPKO Health to Acquire Bio-Reference Laboratories - Complementary in-depth expertise in diagnostics business with state of the art experience in use of genomic data for personalized therapy - Acquisition

More information

MOBILE HEALTHCARE APPDRAGON SMARTMED

MOBILE HEALTHCARE APPDRAGON SMARTMED APPDRAGON SMARTMED With a rapid increase of chronic conditions such as diabetes, obesity, heart disease and respiratory problems, healthcare providers are under increasing pressure to deliver quality care,

More information

Respiratory Care. A Life and Breath Career for You!

Respiratory Care. A Life and Breath Career for You! Respiratory Care A Life and Breath Career for You! Respiratory Care Makes a Difference At 9:32 am, Lori Moreno brought a newborn baby struggling to breathe back to life What have you accomplished today?

More information

Population Health Management Program

Population Health Management Program Population Health Management Program Program (formerly Disease Management) is dedicated to improving our members health and quality of life. Our Population Health Management Programs aim to improve care

More information

Activating Standardization Bodies Around Medical Apps

Activating Standardization Bodies Around Medical Apps Activating Standardization Bodies Around Medical Apps Michael J. Ackerman, Ph.D. Assistant Director High Performance Computing and Communications U.S. National Library of Medicine The views and opinions

More information

Self Care in New Zealand

Self Care in New Zealand Self Care in New Zealand A roadmap toward greater personal responsibility in managing health Prepared by the New Zealand Self Medication Industry Association. July 2009 What is Self Care? Self Care describes

More information

The Board reviews risks to the Company s business plan at its scheduled meetings.

The Board reviews risks to the Company s business plan at its scheduled meetings. Pharmaxis Ltd 1. Board responsibility The Pharmaxis Board is responsible for ensuring the Company establishes and maintains a risk management framework for the oversight and management of risk. The Board

More information

Board Members. Dr Martin Altmann GP Rural Obstetrics. MB, BS (Adelaide) DIP RANZCOG (Advanced) MRCGP (UK) FACRRM

Board Members. Dr Martin Altmann GP Rural Obstetrics. MB, BS (Adelaide) DIP RANZCOG (Advanced) MRCGP (UK) FACRRM MIGA s Boards reflect significant diversity of in all key areas relevant to leading a medical indemnity insurer in Australia. Dr Martin Altmann GP Rural Obstetrics Chairman: MDASA Ltd and Medical Insurance

More information

FUTURE OF HEALTHCARE USING WIRELESS MONITORS

FUTURE OF HEALTHCARE USING WIRELESS MONITORS FUTURE OF HEALTHCARE USING WIRELESS MONITORS Masako Miyazaki, Associate Professor Faculty of Rehabilitation Medicine, University of Alberta Masako.Miyazaki@ualberta.ca www.kanatahealth.ca Presented at

More information

Investora 2015 Dr. Stephan Rietiker, CEO

Investora 2015 Dr. Stephan Rietiker, CEO Investora 2015 Dr. Stephan Rietiker, CEO 1. October 2015 Safe Harbor Statement This communication contains statements that constitute forward-looking statements. Such forward-looking statements include,

More information

Telehealth. Putting the patient at the heart of the journey

Telehealth. Putting the patient at the heart of the journey Telehealth Putting the patient at the heart of the journey Why telehealth? 1 Telehealth is the remote monitoring of a patient s vital signs and symptoms in their own home proven to enhance the quality

More information

Results Q2 &H1. August 24, 2001

Results Q2 &H1. August 24, 2001 Results Q2 &H1 August 24, 2001 Contents Section 1 Company overview and highlights Q2 2001 Erez Alroy, Co-President Section 2 Insight Information Technology Irit Alroy, VP Technology Development Section

More information

Prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation (AF) with one or more risk factors

Prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation (AF) with one or more risk factors News Release For use outside the US and UK only Bayer Pharma AG 13342 Berlin Germany Tel. +49 30 468-1111 www.bayerpharma.com Bayer s Xarelto Approved in the EU for the Prevention of Stroke in Patients

More information

Wandsworth Respiratory Clinical Reference Group Annual Progress Report 2014/15

Wandsworth Respiratory Clinical Reference Group Annual Progress Report 2014/15 Wandsworth Respiratory Clinical Reference Group Annual Progress Report 2014/15 April 2015 Dr Kieron Earney & Kate Symons Acknowledgements Dr Sarah Deedat Public Health Lead for Long Term Conditions 1 1.

More information

University of Ontario Institute of Technology

University of Ontario Institute of Technology University of Ontario Institute of Technology Leveraging key data to provide proactive patient care Overview The need To better detect subtle warning signs of complications, clinicians need to gain greater

More information

Better Outcomes for People Living with Chronic and Complex Health Conditions through Primary Health Care

Better Outcomes for People Living with Chronic and Complex Health Conditions through Primary Health Care Submission: Primary Health Care Advisory Group Discussion Paper (August 2015) Better Outcomes for People Living with Chronic and Complex Health Conditions through Primary Health Care August 2015 Contact

More information

Intro Who should read this document 2 Key Messages 2 Background 2

Intro Who should read this document 2 Key Messages 2 Background 2 Classification: Policy Lead Author: Nathan Griffiths, Consultant Nurse Paediatric Emergency Medicine Additional author(s): N/A Authors Division: Salford Healthcare Unique ID: DDCPan04(14) Issue number:

More information

Internet of Things on HealthCare and Chinese Wearable Medical Devices

Internet of Things on HealthCare and Chinese Wearable Medical Devices Internet of Things on HealthCare and Chinese Wearable Medical Devices Xia Wenhuan Director, Greater China Region Business Development TIP Group wenhuan.xia@transpacificip.com BD Internal INTERNET OF THINGS

More information

GCE AS/A level 1661/01A APPLIED SCIENCE UNIT 1. Pre-release Article for Examination in January 2010 JD*(A09-1661-01A)

GCE AS/A level 1661/01A APPLIED SCIENCE UNIT 1. Pre-release Article for Examination in January 2010 JD*(A09-1661-01A) GCE AS/A level 1661/01A APPLIED SCIENCE UNIT 1 Pre-release Article for Examination in January 2010 JD*(A09-1661-01A) 2 BLANK PAGE 3 Information for Teachers The attached article on asthma is based on some

More information

Mobile Devices Accelerate Patient Centric Healthcare

Mobile Devices Accelerate Patient Centric Healthcare Mobile Devices Accelerate Patient Centric Healthcare Steven F. Owens 1, MedNest, LLC As this web enabled digital age evolves from desktop computers with modems to mobile computing devices and sensors capable

More information

Investor News. Not intended for U.S. and UK media

Investor News. Not intended for U.S. and UK media Investor News Not intended for U.S. and UK media Bayer AG Investor Relations 51368 Leverkusen Germany www.investor.bayer.com Bayer s Xarelto (Rivaroxaban) Approved for the Treatment of Pulmonary Embolism

More information

Acquisition of Decimal

Acquisition of Decimal Acquisition of Decimal Investor Presentation January 2014 www.decimal.com.au Aviva Corporation Ltd www.avivacorp.com.au ABN 31 009 235 956 About Decimal Decimal is an industry-wide financial advice, sales

More information

Wireless Remote Monitoring System for ASTHMA Attack Detection and Classification

Wireless Remote Monitoring System for ASTHMA Attack Detection and Classification Department of Telecommunication Engineering Hijjawi Faculty for Engineering Technology Yarmouk University Wireless Remote Monitoring System for ASTHMA Attack Detection and Classification Prepared by Orobh

More information

Medical Technology - Industry Assistance in Queensland. 30 May 2014

Medical Technology - Industry Assistance in Queensland. 30 May 2014 Medical Technology - Industry Assistance in Queensland 30 May 2014 0 mtaa.org.au Medical technology for a healthier Australia www.mtaa.org.au Level 12, 54 Miller St, North Sydney NSW 2060 Australia PO

More information

Breathe With Ease. Asthma Disease Management Program

Breathe With Ease. Asthma Disease Management Program Breathe With Ease Asthma Disease Management Program MOLINA Breathe With Ease Pediatric and Adult Asthma Disease Management Program Background According to the National Asthma Education and Prevention Program

More information

For personal use only

For personal use only ASX: SWW 14 August 2014 Market Announcements Platform Australian Securities Exchange Level 4 Exchange Centre 20 Bridge Street Sydney NSW 2000 ASX Announcement SWW ENTERS CONDITIONAL AGREEMENT TO ACQUIRE

More information

OPEN INNOVATION STRATEGIES IN THE HEALTHCARE INDUSTRY

OPEN INNOVATION STRATEGIES IN THE HEALTHCARE INDUSTRY NINESIGMA WHITE PAPER OPEN INNOVATION STRATEGIES IN THE HEALTHCARE INDUSTRY How six leading healthcare companies are leveraging Open Innovation to achieve their innovation goals By: Stephen Clulow, Director

More information

Improving Asthma Diagnosis and Treatment

Improving Asthma Diagnosis and Treatment Improving Asthma Diagnosis and Treatment January 2015 Contents/Agenda Introduction to Aerocrine Preliminary Q4/YTD 2014 Highlights Aerocrine Evolution NOT FOR DISTRIBUTION IN OR TO THE U.S. (OR TO U.S.

More information

Connected drug delivery systems : Increase patient compliance and enable comprehensive, coordinated treatments

Connected drug delivery systems : Increase patient compliance and enable comprehensive, coordinated treatments Connected drug delivery systems : Increase patient compliance and enable comprehensive, coordinated treatments Eric Dessertenne, PharmD, MBA Head of Business Development & Commercial Operations edessertennne@biocorp.fr

More information

Breathing Easier In Tennessee: Employers Mitigate Health and Economic Costs of Chronic Obstructive Pulmonary Disease

Breathing Easier In Tennessee: Employers Mitigate Health and Economic Costs of Chronic Obstructive Pulmonary Disease Breathing Easier In Tennessee: Employers Mitigate Health and Economic Costs of Chronic Obstructive Pulmonary Disease By John W. Walsh, Co-Founder and President of the COPD Foundation Breathing Easier In

More information

A simple solution for your complex patients. The market-leading servo ventilation device System One BiPAP autosv

A simple solution for your complex patients. The market-leading servo ventilation device System One BiPAP autosv A simple solution for your complex patients The market-leading servo ventilation device System One BiPAP autosv Advanced simplifies treating complex sleep-disordered breathing patients Developed for your

More information

The Digital Health Trends Poised to Transform Healthcare in 2015. The time to embrace digital health is now. Validic s CEO Ryan Beckland explains.

The Digital Health Trends Poised to Transform Healthcare in 2015. The time to embrace digital health is now. Validic s CEO Ryan Beckland explains. The Digital Health Trends Poised to Transform Healthcare in 2015 The time to embrace digital health is now. Validic s CEO Ryan Beckland explains. There is no question that 2014 was an exciting and eventful

More information

ASTHMA IN INFANTS AND YOUNG CHILDREN

ASTHMA IN INFANTS AND YOUNG CHILDREN ASTHMA IN INFANTS AND YOUNG CHILDREN What is Asthma? Asthma is a chronic inflammatory disease of the airways. Symptoms of asthma are variable. That means that they can be mild to severe, intermittent to

More information

LBT INNOVATIONS TO PRESENT AT AUSBIOTECH BROKER MEETS BIOTECH EVENT

LBT INNOVATIONS TO PRESENT AT AUSBIOTECH BROKER MEETS BIOTECH EVENT The Manager Company Announcements Office ASX Limited LBT INNOVATIONS TO PRESENT AT AUSBIOTECH BROKER MEETS BIOTECH EVENT Adelaide, Australia, 22 September 2016: The newly-appointed Chief Executive Officer

More information

National Clinical Programmes

National Clinical Programmes National Clinical Programmes Section 3 Background information on the National Clinical Programmes Mission, Vision and Objectives July 2011 V0. 6_ 4 th July, 2011 1 National Clinical Programmes: Mission

More information

Tungsten Corporation PLC. Successful placing to raise 160 million significantly over subscribed. Admission to Trading on AIM

Tungsten Corporation PLC. Successful placing to raise 160 million significantly over subscribed. Admission to Trading on AIM NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART, IN, INTO OR FROM THE UNITED STATES, CANADA, AUSTRALIA, JAPAN NOR ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT

More information

1a-b. Title: Clinical Decision Support Helps Memorial Healthcare System Achieve 97 Percent Compliance With Pediatric Asthma Core Quality Measures

1a-b. Title: Clinical Decision Support Helps Memorial Healthcare System Achieve 97 Percent Compliance With Pediatric Asthma Core Quality Measures 1a-b. Title: Clinical Decision Support Helps Memorial Healthcare System Achieve 97 Percent Compliance With Pediatric Asthma Core Quality Measures 2. Background Knowledge: Asthma is one of the most prevalent

More information

Pennino Corporation TECHNOLOGY TO IMPROVE LIFE

Pennino Corporation TECHNOLOGY TO IMPROVE LIFE Pennino Corporation TECHNOLOGY TO IMPROVE LIFE Agenda The Opportunity Highlights Corporate Profile NYU Relationship Obesity and Diabetes Graphics and Facts Next Stage of Development Efficacy and Safety

More information

Healthcare Informatics and Clinical Decision Support. Deborah DiSanzo CEO Healthcare Informatics, Philips Healthcare

Healthcare Informatics and Clinical Decision Support. Deborah DiSanzo CEO Healthcare Informatics, Philips Healthcare Healthcare Informatics and Clinical Decision Support Deborah DiSanzo CEO Healthcare Informatics, Philips Healthcare Leading the way Providing breakthroughs for more than a century * 1988 Technology was

More information

First Warning Systems, Inc.

First Warning Systems, Inc. First Warning Systems, Inc. Breast Cancer Early Detection System US EU/UK & Russia Executive Summary September 2012 i 1. EXECUTIVE SUMMARY 1.1 FIRST WARNING SYSTEM INTRODUCTION First Warning System (FWS)

More information

MEPTEC Medical Technology Conference The Quantified Self: New Mobile Healthcare Technology for Consumers

MEPTEC Medical Technology Conference The Quantified Self: New Mobile Healthcare Technology for Consumers MEPTEC Medical Technology Conference The Quantified Self: New Mobile Healthcare Technology for Consumers Tony Massimini Chief of Technology Semico Research Corp. Sept 18, 2013 tonym@semico.com Outline

More information

Board Members. Dr John O Loughlin AO Obstetrician and Gynaecologist

Board Members. Dr John O Loughlin AO Obstetrician and Gynaecologist MIGA s Boards reflect significant diversity of in all key areas relevant to leading a medical indemnity insurer in Australia. Dr John O Loughlin AO Obstetrician and Gynaecologist Chairman: Chairman: MDASA

More information

HSE Transformation Programme. to enable people live healthier and more fulfilled lives. Easy Access-public confidence- staff pride

HSE Transformation Programme. to enable people live healthier and more fulfilled lives. Easy Access-public confidence- staff pride HSE Transformation Programme. to enable people live healthier and more fulfilled lives Easy Access-public confidence- staff pride The Health Service Executive 4.1 Chronic Illness Framework July 2008 1

More information

FDA Regulation of Health IT

FDA Regulation of Health IT FDA Regulation of Health IT May 2014 Marian J. Lee Partner King & Spalding +1 (202) 661 7955 mlee@kslaw.com Agenda FDA s Mobile Medical Applications Guidance FDASIA Health IT Report 2 FDA s Mobile Medical

More information

Australian Safety and Quality Framework for Health Care

Australian Safety and Quality Framework for Health Care Activities for MANAGERS Australian Safety and Quality Framework for Health Care Putting the Framework into action: Getting started Contents Principle: Consumer centred Area for action: 1.1 Develop methods

More information

MoSHCA My Smart Mobile Healthcare Assistant. Hendrik R. Schwietert, Evalan Henk.Schwietert@Evalan.com

MoSHCA My Smart Mobile Healthcare Assistant. Hendrik R. Schwietert, Evalan Henk.Schwietert@Evalan.com MoSHCA My Smart Mobile Healthcare Assistant Hendrik R. Schwietert, Evalan Henk.Schwietert@Evalan.com MoSHCA Mobility 610,000 Hip Fractures per Year 2 MoSHCA COPD 3% of Population 3 MoSHCA Methodology Monitor

More information

EMA Reaffirms Positive Benefit-Risk Balance of Bayer s Xarelto for Stroke Prevention in Patients with Atrial Fibrillation

EMA Reaffirms Positive Benefit-Risk Balance of Bayer s Xarelto for Stroke Prevention in Patients with Atrial Fibrillation Investor News Not intended for U.S. and UK Media Bayer AG Investor Relations 51368 Leverkusen Germany www.investor.bayer.com EMA Reaffirms Positive Benefit-Risk Balance of Bayer s Xarelto for Stroke Prevention

More information

Australia Life Sciences Market

Australia Life Sciences Market Australia Life Sciences Market Monique Roos, Commercial Specialist U.S. Commercial Service, Sydney, Australia November 2014 Geographical Size Population Density More than 80% of population in this ring

More information

Global Market Study on Sleep Aids: Sleep Apnea to Witness Highest Growth by 2020

Global Market Study on Sleep Aids: Sleep Apnea to Witness Highest Growth by 2020 Brochure More information from http://www.researchandmarkets.com/reports/3422615/ Global Market Study on Sleep Aids: Sleep Apnea to Witness Highest Growth by 2020 Description: Sleep aids are pills and

More information

Creating an international pharmacy-led healthcare group

Creating an international pharmacy-led healthcare group 3 October 2005 Alliance Boots plc 1 Legal disclaimer This presentation does not constitute an offer to sell or the solicitation of an offer to subscribe for or buy any security, nor shall there be any

More information

Healthcare 2014: Driving efficiency through technology. Part two: Chronic Disease Management and Preventative Health

Healthcare 2014: Driving efficiency through technology. Part two: Chronic Disease Management and Preventative Health Healthcare 2014: Driving efficiency through technology Alex Holderness for Australian Healthcare Week 2014 Technology is sitting right at the heart of the healthcare efficiency drive and it s easy to see

More information

Skill Levels for Delivering High Quality Asthma and COPD Respiratory Care by Nurses in Primary Care

Skill Levels for Delivering High Quality Asthma and COPD Respiratory Care by Nurses in Primary Care Skill Levels for Delivering High Quality Asthma and COPD Respiratory Care by Nurses in Primary Care September 2007 Revised December 2009, April 2014 Author: Ruth McArthur In conjunction with the PCRS-UK

More information

EXPANSION INTO ALLIED HEALTHCARE AND KEY MANAGEMENT APPOINTMENTS

EXPANSION INTO ALLIED HEALTHCARE AND KEY MANAGEMENT APPOINTMENTS ASX Release EXPANSION INTO ALLIED HEALTHCARE AND KEY MANAGEMENT APPOINTMENTS Melbourne, Australia; 15 January 2016: Jayex Healthcare Limited (ASX:JHL) (JHL or Company) is pleased to announce that, since

More information

Innovations in Diabetes. Angela Blair Channel Manager RN Credentialled Diabetes Educator

Innovations in Diabetes. Angela Blair Channel Manager RN Credentialled Diabetes Educator Innovations in Diabetes Angela Blair Channel Manager RN Credentialled Diabetes Educator Innovations Time - $$$ Innovations & Technology Blood Testing Insulin delivery devices Insulin pumps Pills & Potions

More information

Healthcare, Regulatory and Reimbursement Landscape - Australia

Healthcare, Regulatory and Reimbursement Landscape - Australia Brochure More information from http://www.researchandmarkets.com/reports/2207850/ Healthcare, Regulatory and Reimbursement Landscape - Australia Description: Healthcare, Regulatory and Reimbursement Landscape

More information

Cautionary Statement

Cautionary Statement Cautionary Statement The following document contains certain forward-looking statements and forward-looking information, which is based on current expectations, estimates, projections, assumptions and

More information

The challenge. What we did. Highlights. Designing and delivering scalable telemonitoring and telecare through partnership.

The challenge. What we did. Highlights. Designing and delivering scalable telemonitoring and telecare through partnership. Telehealthcare Designing and delivering scalable telemonitoring and telecare through partnership The challenge Northern Ireland has a population of approximately 1.8 million people. Around two thirds of

More information

Illuminating the Pathways to Commercialisation Workshop for health and medical researchers

Illuminating the Pathways to Commercialisation Workshop for health and medical researchers A joint initiative of the National Health and Medical Research Council (NHMRC) and the Department of Industry 14 November 2014, 09:30 16:30 AEDST Brisbane Room, Level 1, Sofitel Melbourne on Collins 25

More information

Challenge of FUJIFILM in Medical ICT

Challenge of FUJIFILM in Medical ICT Challenge of FUJIFILM in Medical ICT Sep.10, 2014 FORWARD-LOOKING STATEMENTS Forward-looking statements, such as those relating to earnings forecasts and other projections contained in this material, are

More information

The Annual Direct Care of Asthma

The Annual Direct Care of Asthma The Annual Direct Care of Asthma The annual direct health care cost of asthma in the United States is approximately $11.5 billion; indirect costs (e.g. lost productivity) add another $4.6 billion for a

More information

STATES OF JERSEY DRAFT HEALTH INSURANCE FUND (MISCELLANEOUS PROVISIONS) (JERSEY) LAW 201- STATES GREFFE

STATES OF JERSEY DRAFT HEALTH INSURANCE FUND (MISCELLANEOUS PROVISIONS) (JERSEY) LAW 201- STATES GREFFE STATES OF JERSEY r DRAFT HEALTH INSURANCE FUND (MISCELLANEOUS PROVISIONS) (JERSEY) LAW 201- Lodged au Greffe on 13th September 2010 by the Minister for Social Security STATES GREFFE 2010 Price code: C

More information

Theravance Biopharma, Inc. Reports Second Quarter 2015 Financial Results and Provides Business Update

Theravance Biopharma, Inc. Reports Second Quarter 2015 Financial Results and Provides Business Update August 10, 2015 Theravance Biopharma, Inc. Reports Second Quarter 2015 Financial Results and Provides Business Update DUBLIN, IRELAND -- (Marketwired) -- 08/10/15 -- Theravance Biopharma, Inc. (NASDAQ:

More information

Use of Mobile Medical Applications in Clinical Research

Use of Mobile Medical Applications in Clinical Research Use of Mobile Medical Applications in Clinical Research Erin K. O Reilly, PhD RAC Associate Director, Regulatory Affairs Duke Translational Medicine Institute erin.oreilly@duke.edu September 10, 2014 (919)

More information

WHITE PAPER. M-Health: Challenges, benefits, and keys to successful implementation. Abstract

WHITE PAPER. M-Health: Challenges, benefits, and keys to successful implementation. Abstract WHITE PAPER M-Health: Challenges, benefits, and keys to successful implementation Kaushal Modi and Radha Baran Mohanty Abstract The outlook towards healthcare has changed drastically in recent times. Mobile

More information

An introduction to Optos

An introduction to Optos An introduction to Optos Building The Retina Company Roy Davis, CEO Christine Soden, CFO 1 Forward-Looking Statements Certain statements made in this presentation are forward-looking statements. These

More information

Onthehouse MD and CRO on growth outlook for Consumer Online division

Onthehouse MD and CRO on growth outlook for Consumer Online division Level 9, 348 Edward Street Brisbane QLD 4000 Attention: ASX Company Announcements Platform Lodgement of Market Briefing 20 November 2013 Onthehouse MD and CRO on growth outlook for Consumer Online division

More information

FEBRUARY 2015. Knowledge. Insight. Commitment.

FEBRUARY 2015. Knowledge. Insight. Commitment. CoRPORATE PrOfile FEBRUARY 2015 PHILOSOPHY Knowledge At the heart of our business philosophy is this singular truth: knowledge is power. The partners of Horwood Associates are not only experts in their

More information

Prof. D K Arvind School of Informatics, University of Edinburgh

Prof. D K Arvind School of Informatics, University of Edinburgh Remote Monitoring of DDDDDDDDD COPD Patients using Speckled Computing the Elgin Experience Prof. D K Arvind School of Informatics, University of Edinburgh Partners The Moray Council NHS Grampian The Maryhill

More information

Primary Health Networks Life After Medicare Locals

Primary Health Networks Life After Medicare Locals Health Industry Group Primary Health Networks Life After Medicare Locals BULLETIN 2 25 MARCH 2015 HEALTH INDUSTRY GROUP BULLETIN a Federal health policy is changing with 30 Primary Health Networks (PHNs)

More information

FDA Issues Final Guidance on Mobile Medical Apps

FDA Issues Final Guidance on Mobile Medical Apps ADVISORY September 2013 FDA Issues Final Guidance on Mobile Medical Apps On September 23, 2013, the U.S. Food & Drug Administration (FDA or the Agency) issued its final Guidance for Industry and Food and

More information

Prognosis for Healthcare: The Future of Medicine

Prognosis for Healthcare: The Future of Medicine Prognosis for Healthcare: The Future of Medicine Bruce M. Cohen, M.D., Ph.D. Director, Frazier Research Institute, McLean Hospital President and Psychiatrist in Chief Emeritus, McLean Hospital Robertson-Steele

More information

Tabcorp Holdings Limited (ABN 66 063 780 709) Tabcorp Holdings Limited (ABN 66 063 780 709)

Tabcorp Holdings Limited (ABN 66 063 780 709) Tabcorp Holdings Limited (ABN 66 063 780 709) 1 Tabcorp Holdings Limited (ABN 66 063 780 709) Tabcorp Holdings Limited (ABN 66 063 780 709) Wagering segment of the gambling market Tabcorp has improved market share in a highly competitive environment

More information

ASX Announcement Takeover bid for Vision Eye Institute

ASX Announcement Takeover bid for Vision Eye Institute 6 July 2015 ASX Announcement Takeover bid for Vision Eye Institute Pulse Health Limited ( Pulse ; ASX: PHG) is pleased to announce a takeover bid for Vision Eye Institute Limited ( Vision ; ASX: VEI) comprising

More information

Herald Investment Management June 2015. Herald Investment Management Ltd is authorised and regulated by the Financial Conduct Authority

Herald Investment Management June 2015. Herald Investment Management Ltd is authorised and regulated by the Financial Conduct Authority Herald Investment Management June 2015 Herald Investment Management Ltd is authorised and regulated by the Financial Conduct Authority This presentation is intended for professional investors only Investors

More information

George Savvides Managing Director

George Savvides Managing Director George Savvides Managing Director Macquarie Australia Conference, 8 May 2015 IMPORTANT NOTICE The information contained in this presentation is for information purposes only. The information contained

More information

JDRF Type One Nation Research Summit Diabetes Technology: A Bridge to a Cure

JDRF Type One Nation Research Summit Diabetes Technology: A Bridge to a Cure JDRF Type One Nation Research Summit Diabetes Technology: A Bridge to a Cure Kelly L. Close, president, Close Concerns editor-in-chief, diatribe March 1, 2014 closeconcerns.com diatribe.org @diatribenews

More information

2009 Foley & Lardner LLP Attorney Advertising Prior results do not guarantee a similar outcome Models used are not clients but may be representative

2009 Foley & Lardner LLP Attorney Advertising Prior results do not guarantee a similar outcome Models used are not clients but may be representative Attorney Advertising Prior results do not guarantee a similar outcome Models used are not clients but may be representative of clients 321 N. Clark Street, Suite 2800, Chicago, IL 60654 312.832.4500 Life

More information

Home Healthcare Solutions. Don Spence CEO Home Healthcare Solutions Philips Healthcare

Home Healthcare Solutions. Don Spence CEO Home Healthcare Solutions Philips Healthcare Home Healthcare Solutions Don Spence CEO Home Healthcare Solutions Philips Healthcare The transformation of care in the home is required to address demographic changes The issues The consequences Our responses

More information

London Stock Exchange Symbol: PLUS

London Stock Exchange Symbol: PLUS London Stock Exchange Symbol: PLUS 1 Disclaimer The Presentation does not constitute or form part of any offer or invitation to sell or issue, or any solicitation of any offer to purchase or subscribe

More information

ACQUISITION OF IODM PTY LTD CLOUD BASED AUTOMATED DEBTOR MANAGEMENT SOLUTION

ACQUISITION OF IODM PTY LTD CLOUD BASED AUTOMATED DEBTOR MANAGEMENT SOLUTION ACQUISITION OF IODM PTY LTD CLOUD BASED AUTOMATED DEBTOR MANAGEMENT SOLUTION ABN 28 102 747 133 ASX Release 29 December 2015 Level 1/330 Churchill Avenue Subiaco WA 6008 Ph: +61 8 9200-4482 Fax: +61 8

More information

Biotech Daily. Wednesday February 5, 2014. Daily news on ASX-listed biotechnology companies * ASX, BIOTECH DOWN: REVA UP 10%, CIRCADIAN DOWN 11%

Biotech Daily. Wednesday February 5, 2014. Daily news on ASX-listed biotechnology companies * ASX, BIOTECH DOWN: REVA UP 10%, CIRCADIAN DOWN 11% Biotech Daily Wednesday February 5, 2014 Daily news on ASX-listed biotechnology companies * ASX, BIOTECH DOWN: REVA UP 10%, CIRCADIAN DOWN 11% * ACRUX TELLS ASX: REPORT CUT PRICE 10%, $US50m 2015 MILESTONE

More information

ASX Announcement. Presentation by David Griffith to Morgans Conference

ASX Announcement. Presentation by David Griffith to Morgans Conference ASX Announcement 21 October 2015 Presentation by David Griffith to Morgans Conference Attached is a presentation to be given later today by IPH s Managing Director, David Griffith to the Morgans Annual

More information

RXP SERVICES LIMITED ABN 30 146 959 917. Release to Australian Stock Exchange

RXP SERVICES LIMITED ABN 30 146 959 917. Release to Australian Stock Exchange RXP Services Limited Level 9, 406 Collins Street MELBOURNE VIC 3000 Phone +61 3 8256 4855 www.rxpservices.com.au RXP SERVICES LIMITED ABN 30 146 959 917 Release to Australian Stock Exchange 8 April 2014

More information

The Biotech Business Life Cycle. The Lawyer s Role as Counselor and Advisor

The Biotech Business Life Cycle. The Lawyer s Role as Counselor and Advisor The Biotech Business Life Cycle and The Lawyer s Role as Counselor and Advisor ASU February 15, 2010 1 BIOTECH BUSINESS CYCLE AN INTERDISCIPLINARY APPROACH TO LEGAL REPRESENTATION Intellectual Property

More information

National Institute for Health and Care Excellence. NICE Quality Standards Consultation Idiopathic Pulmonary Fibrosis

National Institute for Health and Care Excellence. NICE Quality Standards Consultation Idiopathic Pulmonary Fibrosis National Institute for Health and Care Excellence NICE Quality Standards Consultation Idiopathic Pulmonary Fibrosis Closing date: 5pm Tuesday 23 September 2014 Organisation Title Name Job title or role

More information

FDA Regulation of Health IT

FDA Regulation of Health IT FDA Regulation of Health IT September 2014 Marian J. Lee Partner +1 (202) 661 7955 mlee@kslaw.com Agenda FDA s Mobile Medical Applications Guidance FDA Draft Guidance on Medical Device Data Systems (MDDS),

More information

The Future of Consumer Health Care

The Future of Consumer Health Care The Future of Consumer Health Care Coming Together To Lead The Consumer Health Care Industry 2 Creating a New Business Model in Consumer Health Care 3 Serve More Consumers In More Parts of the World, More

More information

Property is at the core of everything we do

Property is at the core of everything we do Corporate Profile Overview Trilogy Funds has a strong background in structuring and managing property investments. Trilogy Funds reputation is based on the experience and strengths of its key executives.

More information

BOARD PAPER - NHS ENGLAND. Purpose of Paper: To inform the Board about progress on implementation of the Cancer Taskforce report.

BOARD PAPER - NHS ENGLAND. Purpose of Paper: To inform the Board about progress on implementation of the Cancer Taskforce report. Paper: PB.28.01.16/05 Title: Cancer Taskforce strategy implementation Lead Director: Bruce Keogh, National Medical Director Cally Palmer, National Cancer Director BOARD PAPER - NHS ENGLAND Purpose of Paper:

More information

For personal use only. November 2015. Wholesale Investor - London (UK) Presentation

For personal use only. November 2015. Wholesale Investor - London (UK) Presentation November 2015 Wholesale Investor - London (UK) Presentation 1 Overview Capitalising on global mobile growth! Crowd Mobile is a global mobile company with a focus on the growing mobile economy.! We have

More information

Enabling Integrated Care

Enabling Integrated Care Enabling Integrated Care Harnessing personal health systems for better outcomes across the care continuum Briefing Note for a SmartPersonalHealth Workshop WoHIT, Thursday 18 March 2010, 13:00-17:00, Barcelona

More information

Agreement with Philips for US Business Conference Call Presentation 4 October 2007, 10am CET

Agreement with Philips for US Business Conference Call Presentation 4 October 2007, 10am CET Agreement with Philips for US Business Conference Call Presentation 4 October 2007, 10am CET Dial-in Details +41 91 610 5600 (Europe/Israel) +1 (1) 866 291 4166 (USA) +44 207 107 0611 (UK) SHL at a Glance

More information